bluebird bio Inc (NASDAQ:BLUE) insider Jeffrey T. Walsh sold 3,000 shares of the business’s stock in a transaction on Wednesday, January 16th. The shares were sold at an average price of $125.14, for a total value of $375,420.00. Following the completion of the sale, the insider now directly owns 35,483 shares in the company, valued at approximately $4,440,342.62. The sale was disclosed in a legal filing with the SEC, which is available through this link.
bluebird bio stock opened at $129.96 on Friday. bluebird bio Inc has a 52 week low of $87.49 and a 52 week high of $236.17.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Thursday, November 1st. The biotechnology company reported ($2.73) EPS for the quarter, topping analysts’ consensus estimates of ($2.90) by $0.17. The company had revenue of $11.50 million for the quarter, compared to analyst estimates of $6.90 million. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The business’s revenue was up 49.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($1.73) earnings per share. Analysts anticipate that bluebird bio Inc will post -10.62 EPS for the current year.
Several analysts recently commented on BLUE shares. Cowen reaffirmed a “buy” rating on shares of bluebird bio in a research note on Friday, November 2nd. William Blair reaffirmed a “buy” rating on shares of bluebird bio in a research note on Thursday, November 1st. ValuEngine lowered bluebird bio from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 16th. Janney Montgomery Scott raised bluebird bio from a “neutral” rating to a “buy” rating and set a $170.00 price target on the stock in a research note on Monday, November 5th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of bluebird bio in a research note on Sunday, November 4th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. bluebird bio presently has a consensus rating of “Buy” and a consensus target price of $188.83.
A number of institutional investors have recently bought and sold shares of BLUE. Cornerstone Advisors Inc. raised its position in shares of bluebird bio by 1,540.0% during the fourth quarter. Cornerstone Advisors Inc. now owns 328 shares of the biotechnology company’s stock worth $33,000 after acquiring an additional 308 shares during the last quarter. Stratos Wealth Partners LTD. bought a new stake in shares of bluebird bio during the third quarter worth $106,000. Belpointe Asset Management LLC bought a new stake in shares of bluebird bio during the third quarter worth $110,000. NuWave Investment Management LLC raised its position in shares of bluebird bio by 10,811.1% during the third quarter. NuWave Investment Management LLC now owns 982 shares of the biotechnology company’s stock worth $143,000 after acquiring an additional 973 shares during the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. raised its position in shares of bluebird bio by 635.0% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,154 shares of the biotechnology company’s stock worth $167,000 after acquiring an additional 997 shares during the last quarter.
WARNING: “Insider Selling: bluebird bio Inc (BLUE) Insider Sells 3,000 Shares of Stock” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another domain, it was stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2019/01/20/insider-selling-bluebird-bio-inc-blue-insider-sells-3000-shares-of-stock.html.
About bluebird bio
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.
Featured Story: Debt-To-Equity Ratio
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.